Adaptimmune Therapeutics Ownership | Who Owns Adaptimmune Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Adaptimmune Therapeutics Ownership Summary

Adaptimmune Therapeutics is owned by 7.49% institutional investors, 0.63% insiders, and 91.88% retail investors. Bank of america corp /de/ is the largest institutional shareholder, holding 1.92% of ADAP shares. Edinburgh Worldwide Ord is the top mutual fund, with 2.00% of its assets in Adaptimmune Therapeutics shares.

ADAP Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Adaptimmune Therapeutics	7.49%	0.63%	91.88%
Sector	Healthcare Stocks	488.17%	11.08%	-399.26%
Industry	Biotech Stocks	307.00%	11.11%	-218.12%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bank of america corp /de/	4.65M	1.92%	$4.53M
Ecor1 capital	27.40M	1.79%	$14.76M
Long focus capital management	23.76M	1.54%	$5.69M
Two seas capital lp	22.58M	1.46%	$5.41M
Nea management company	17.08M	1.11%	$4.09M
Mpm asset management	4.81M	0.31%	$1.15M
Bioimpact capital	4.41M	0.29%	$1.06M
Morgan stanley	440.83K	0.18%	$429.77K
Renaissance	2.53M	0.16%	$1.36M
Rock springs capital management lp	2.48M	0.16%	$595.29K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mpm asset management	4.81M	2.66%	$1.15M
Ecor1 capital	27.40M	0.56%	$14.76M
Nea management company	17.08M	0.31%	$4.09M
Long focus capital management	23.76M	0.22%	$5.69M
Bioimpact capital	4.41M	0.18%	$1.06M
Two seas capital lp	22.58M	0.09%	$5.41M
Rock springs capital management lp	2.48M	0.04%	$595.29K
Key client fiduciary advisors	175.56K	0.02%	$42.08K
Empirical finance	800.00K	0.01%	$191.76K
Columbia advisory partners	36.73K	0.01%	$8.80K

Top Buyers

Holder	Shares	% Assets	Change
Two seas capital lp	22.58M	0.09%	2.05M
Renaissance	2.53M	0.00%	869.95K
Empirical finance	800.00K	0.01%	800.00K
Ubs group	141.74K	-	139.93K
Almitas capital	109.05K	0.01%	109.05K

Top Sellers

Holder	Shares	% Assets	Change
Matrix capital management company, lp	-	-	-37.68M
Baillie gifford	-	-	-11.82M
Pfm health sciences, lp	-	-	-4.87M
Baker bros. advisors lp	-	-	-2.34M
Tang capital management	-	-	-1.74M

New Positions

Holder	Shares	% Assets	Change	Value
Empirical finance	800.00K	0.01%	800.00K	$191.76K
Almitas capital	109.05K	0.01%	109.05K	$26.14K
Xtx topco	80.02K	0.00%	80.02K	$19.18K
Wiley bros.-aintree capital	20.00K	-	20.00K	$4.79K
Kornitzer capital management inc /ks	10.00K	-	10.00K	$2.40K

Sold Out

Holder	Change
National bank of canada /fi/	-10.00
Farther finance advisors	-20.00
Northwestern mutual wealth management	-69.00
Group one trading	-147.00
Royal bank of canada	-700.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	64	-8.57%	115,507,217	-0.49%	7	13.22%	18	-30.77%	20	17.65%
Mar 31, 2025	5	-93.83%	42,678,699	-65.69%	2	4.21%	2	-93.55%	2	-90.48%
Dec 31, 2024	79	-2.47%	124,313,247	-18.02%	8	8.30%	30	-18.92%	21	40.00%
Sep 30, 2024	79	-1.25%	151,643,820	-1.46%	59	1.46%	36	56.52%	15	-31.82%
Jun 30, 2024	80	-3.61%	153,896,694	-5.05%	63	1.25%	23	-32.35%	22	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Edinburgh Worldwide Ord	5.28M	2.00%	-
Baillie Gifford Global Discovery A Acc	3.29M	1.28%	-20.71K
Baillie Gifford WW Discovery B USD Acc	1.59M	0.62%	-6.22K
JPM Thematics Genetic Thrps C2 Acc USD	913.17K	0.36%	-26.08K
JPM Thematics Genetic Thrps C2 dist USD	881.69K	0.34%	-
Galileo - Biotech Innovation Fund S USD	752.46K	0.28%	-
Mercer Global Small Cap Equity M-5£	635.81K	0.25%	-
Mercer Global Small Cap Equity M-3£	484.78K	0.19%	84.40K
SPDR® Portfolio Developed Wld ex-US ETF	285.18K	0.11%	-
A4Investments SICAV SIF ACCI IlanaA2EURH	221.29K	0.09%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 28, 2025	Bertrand William C JR	Chief Operating Officer	Sell	$2.09K
Aug 18, 2025	Behbahani Ali	-	Sell	$176.06K
Aug 15, 2025	Behbahani Ali	-	Sell	$53.11K
Jul 30, 2025	EcoR1 Capital, LLC	-	Sell	$2.80M
Jul 29, 2025	EcoR1 Capital, LLC	-	Sell	$271.97K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	6
2025 Q1	-	17
2024 Q3	-	-
2024 Q2	-	1
2024 Q1	-	19

ADAP Ownership FAQ

Who Owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics shareholders are primarily institutional investors at 7.49%, followed by 0.63% insiders and 91.88% retail investors. The average institutional ownership in Adaptimmune Therapeutics's industry, Biotech Stocks , is 307.00%, which Adaptimmune Therapeutics falls below.

Who owns the most shares of Adaptimmune Therapeutics?

Adaptimmune Therapeutics’s largest shareholders are Bank of america corp /de/ (4.65M shares, 1.92%), Ecor1 capital (27.4M shares, 1.79%), and Long focus capital management (23.76M shares, 1.54%). Together, they hold 5.25% of Adaptimmune Therapeutics’s total shares outstanding.

Does Blackrock own Adaptimmune Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Adaptimmune Therapeutics.

Who is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.66% of its assets in 4.81M Adaptimmune Therapeutics shares, valued at 1.15M$.

Who is the top mutual fund holder of Adaptimmune Therapeutics shares?

Edinburgh Worldwide Ord is the top mutual fund holder of Adaptimmune Therapeutics shares, with 2.00% of its total shares outstanding invested in 5.28M Adaptimmune Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools